Drug discovery and development depends increasingly on imaging, from traditional microscopy to high-content screening. Moreover, these techniques provide sophisticated capabilities. To make the most use of these tools, researchers need advanced software that provides automation, analysis, and ease-of-use.
Johnson & Johnson plans to submit more than 10 new treatments to regulators for approval and...
A majority of medical experts on a U.S. Food and Drug Administration panel said that an...
Hypoactive sexual desire disorder affects 10% of women in the United States and significantly higher percentages of women who have undergone surgical menopause.There are no U.S. Food and Drug Administration-approved treatments for this large, unmet medical need.
Moody's Investors Service has placed Hospira Inc.'s long-term debt rating under review for possible downgrade. The move was based on a concern that the company's performance over the next few years remains uncertain as a result of costs related to its new product strategy and possible regulatory issues.
Pfizer Inc. plans to start selling its remaining stake in the animal health business Zoetis Inc. through a voluntary exchange offer with its shareholders. Shareholders will be able to trade their Pfizer holdings for Zoetis shares at a discount, depending on the number of shares exchanged.
Bristol-Myers Squibb could be a big winner with a portfolio of cancer treatments under development that use a patient's own immune system to attack the disease. Citi analyst Andrew Baum expects that within 10 years, immunotherapy will form the backbone of 60% of all cancer treatment plans in the developed world.
Gibson Assembly is a rapid and reliable method for the assembly of DNA fragments in a single-tube, isothermal reaction without reliance upon the presence of restriction sites within the target sequence. The technique is readily adaptable for site-directed mutagenesis.
AcelRx Pharmaceuticals Inc. announced that its NanoTab pain treatment system met its main goal in late-stage research, and the company is preparing to submit it to regulators for approval. Patients using the system experienced a significantly greater reduction in pain than those taking a placebo.
GlaxoSmithKline has launched Discovery Fast Track, a competition designed to accelerate academic research into novel therapies. Winners will partner with investigators on GSK’s Discovery Partnerships with Academia team to turn research-stage drug candidates into innovative medicines.
A new study of both computer-created and natural proteins suggests that the number of unique pockets– sites where small molecule pharmaceutical compounds can bind to proteins– is surprisingly small, meaning drug side effects may be impossible to avoid.
A Phase 2a trial of dupilumab showed that the experimental monoclonal antibody has the ability to stick to certain inflammatory proteins and significantly reduce acute breathing problems in patients suffering from moderate-to-severe asthma.
Drugmaker Pfizer Inc. has halted a late-stage study of an experimental cancer compound being tested in patients with a certain form of non-Hodgkin's lymphoma, because an interim analysis showed the drug wasn't helping patients live longer.
Rhythm announced the presentation of results from a new epidemiology study demonstrating a higher prevalence of gastroparesis symptoms among diabetic patients in the U.S. than previously recognized. Prevalence of these symptoms is high among patients with both type 1 and type 2 diabetes.
Researchers have discovered how a key player in cell growth, immunity, and the inflammatory response can be transformed into a primary contributor to tumor growth. NF-kappa B induces the transcription of genes that trigger inflammation, promote cell proliferation, and undermine cell death.
U.S. Food and Drug Administration regulators say an experimental insomnia drug from Merck called suvorexant can help patients fall asleep, but it also carries worrisome side effects, including an increased risk of daytime drowsiness and suicidal thinking.
Actavis is buying Warner Chilcott in a transaction valued at about $8.5 billion which would create the third-biggest specialty pharmaceutical company in the U.S. The new company is expected to be called Actavis PLC and will be incorporated in Ireland, where Warner Chilcott is currently incorporated.
Scientists no longer see the painful degenerative disease osteoarthritis as a problem primarily of the cartilage that cushions joints; they now have evidence that the bone underneath the cartilage is also a key player and exacerbates the damage.